• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Venous thromboembolism (VTE) - Articles and news items

Atrial fibrillation market will peak in 2022 before decline to $4.9 Billion by 2025, says GlobalData

Atrial fibrillation market will peak at $11.8 billion in 2022

Industry news / 2 August 2016 / GlobalData

The atrial fibrillation market will expand from approximately $8 billion in 2015 to hit its peak of $11.8 billion in 2022, after which the impact of patent expiries will see the market value fall rapidly to $4.9 billion by 2025, according to research and consulting firm GlobalData…

Blood clot deep vein thrombosis Venous thromboembolism pulmonary embolism

Venous thromboembolism (VTE) therapeutics market set to hit $3.7 billion by 2025

Industry news / 1 August 2016 / GlobalData

Growth will be driven by the uptake of novel oral anticoagulants, which represent important advances over warfarin, a cheap and established anticoagulant, says new report…

edoxaban

Servier Canada to market edoxaban in Canada

Industry news / 27 June 2016 / Victoria White, Digital Content Producer

Edoxaban is an oral anticoagulant that specifically inhibits factor Xa, which is an important factor in the coagulation system that leads to blood clotting…

praxbind

BMS and Pfizer announce new data for Eliquis (apixaban)

Industry news / 11 December 2015 / Victoria White

In the data from the Phase 3 AMPLIFY study, Eliquis (apixaban) was comparable to conventional therapy in recurrent venous thromboembolism (VTE)…

vte

Daiichi Sankyo helps raise awareness of VTE and AF

Industry news / 13 October 2015 / Daiichi Sankyo

Daiichi Sankyo has teamed up with World Thrombosis Day to promote awareness of thrombosis, its causes, risk factors, and signs and symptoms…

clot-edoxaban

NICE recommends edoxaban for deep vein thrombosis

Industry news / 26 August 2015 / Victoria White

NICE has recommended once-daily edoxaban for the treatment and prevention of recurrent DVT and pulmonary embolism, saying the drug is cost-effective for the NHS…

edoxaban

Real world ETNA registries of new once-daily edoxaban start in Europe

Industry news / 24 August 2015 / Victoria White

ETNA registries have commenced in Europe to collect a robust set of information on how once-daily edoxaban is being used in real world settings…

edoxaban

Daiichi Sankyo’s edoxaban launched in the UK

Industry news / 10 July 2015 / Victoria White

Edoxaban, a new blood-thinning drug therapy to help prevent stroke in patients with non-valvular atrial fibrillation, has been launched in the UK…

necitumumab

NICE guidance recommends anti-blood clotting drug apixaban

Industry news / 9 June 2015 / NICE

NICE has recommended the anti-blood clotting drug apixaban as an option for treating and preventing venous thromboembolism (VTE) in adults…

blood-clots

New clinical research programme launched for the prevention and treatment of blood clots in patients with cancer

Industry news / 29 May 2015 / VIctoria White

Janssen and Bayer have launched a clinical research programme evaluating rivaroxaban for the prevention and treatment of blood clots in patients with cancer…

Lixiana

Swissmedic approves Lixiana for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation

Industry news / 15 April 2015 / Daiichi Sankyo

Swissmedic has granted approval of Lixiana for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation…

Daiichi Sankyo logo

U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk

Industry news, News / 9 January 2015 / Daiichi Sankyo

U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk in non-valvular atrial fibrillation and for the treatment of venous thromboembolism…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +